N/A N=52 Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals
Obesity · Overweight
Primary: Change in Interleukin-6 (Value at Week 8 Minus Value at Week 0) — 0.35; -1.08; 0.51 pg/mL — p=0.9942
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=64 Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
Axial Spondyloarthritis
Primary: Proportion of Patients Achieving Sustained Clinical Remission — 34 Participants
N/A N=46 Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome
Dysbiosis · Endotoxemia · Metabolic Syndrome
Primary: Serum Endotoxin — 31.6; 26.7; 44.5; 39.1 EU/mL
Phase 1 N=20 Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Inflammatory Bowel Disease (IBD)
Primary: Clinical Response — 9 Participants — p=0.03
N/A N=15 Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis
Ulcerative Colitis
Primary: Golimumab Induced Shifts in the Abundance of Bacterial Markers — 14965109899; 132857054401767; 12779328208; 12851286145 16S gene copies per gram of faeces
N/A N=34 Effects of Fermented Vegetables on Gut Microflora and Inflammation in Women
Inflammation · Women's Health · Gastrointestinal Microbiome
Primary: C-reactive Protein — 160.7; 173.4; 211.4 ng/mL
Phase 4 N=30 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
N/A N=225 Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
Irritable Bowel Syndrome · Colitis, Ulcerative · Crohn Disease
Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population
N/A N=19 The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis
Ulcerative Colitis
Primary: Change in Dim Light Melatonin Onset (DLMO) From Baseline (Aligned) to Circadian Misalignment Misalignment — 20.72; 20.45; 23.05; 22.65 hours
Phase 1 N=13 Bacteriotherapy in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…
N/A N=15 Autoimmune Protocol Diet and Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
N/A N=15 Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
Crohn Disease
Primary: Change From Baseline in the Crohn's Disease Endoscopic Index of Severity (CDEIS) Blinded Score at Week 6 — -4.8 Score on a scale
N/A N=53 Stress in Inflammatory Bowel Disease
Inflammatory Bowel Diseases · Psychological
Primary: Retention Rate — 23; 25; 19; 22 Participants
Phase 1 N=23 Fecal Microbiota Transplantation in Pediatric Patients
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
N/A N=50 Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
Inflammatory Bowel Disease · Glycogen Storage Disease Type Ia
Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive
Phase 4 N=10 Effect of Antibiotics on Enteric Neurons and Glia
Antibiotic Enterocolitis
Primary: Change in Mean Number of Colonic Submucosal Neurons/mm^2 in the Colon After Antibiotic Treatment — 0 neuronal cells/mm^2
Phase 1 N=31 Biological Signatures, Probiotic Among Those With mTBI and PTSD
Mild Traumatic Brain Injury · Post Traumatic Stress Disorder
Primary: C-Reactive Protein Change — 0.113; -0.625 mg/L — p=.056
N/A N=16 Diet Induced Intestinal Mucosal Adaptation
Healthy Conditions
Primary: Mucosal Surface Enlargement — 10.2; 9.9 percentage of muscular mucosae — p=<0.05
Phase 2 N=94 Inulin for Infections in the Intensive Care Unit
Antibiotic Resistant Infection · Nosocomial Infection · Pathogen Transmission
Primary: Within-individual Change in SCFA Producer Level — -0.0; -1.8; 1.1 percentage of SCFA producers
N/A N=30 Obesity - Inflammation - Metabolic Disease: Effect of Lactobacillus Casei Shirota
Metabolic Syndrome
Primary: Change of Neutrophil Phagocytosis From Baseline to 3 Months — 0.06; 3.48 percentage of monocytes and granulocytes
Phase 2 N=24 A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System
HIV Infection · Gastrointestinal Symptoms
Primary: Effects of Daily Consumption of GanedenBC30 on Immune Function and Gastro-intestinal Issues
Phase 2 N=8 Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Crohn's Disease
Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale
Phase 1 N=21 Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults
Healthy Adults
Primary: To Evaluate the Effect of BSS on the Human Gut Microbiome. — 2 Number of different bacterial taxa — p=<0.05
Phase 2 N=10 Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Crohn Disease
Primary: Change in FCP in Group 2 Participants — 1501 mcg/g — p=1.0
N/A N=25 Diet and Systemic Inflammation
Low-grade Chronic Inflammation · Intestinal Permeability · Type 2 Diabetes Mellitus
Primary: Fasting Plasma C-reactive Protein — 0.91; 1.07; 1.67; 1.09 mg/L — p=0.403
N/A N=13 Effects of Adding Chickpeas to the American Diet on Fecal Microbiota Composition and Markers of Inflammation
Inflammation
Primary: Changes in Diversity of Gut Microbiota 16S rRNA Gene Sequences With Regard to Time. — 316.383; 302.400; 283.058 Avg. Operational Taxonomic Units
N/A N=40 Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults
Obesity · Endotoxemia · Inflammation
Primary: Endotoxin — 14.44; 12.97; 12.25; 17.65 EU/mL
Phase 4 N=33 Mesalamine to Reduce T Cell Activation in HIV Infection
HIV Infections · Sexually Transmitted Diseases · Immune System Diseases
Primary: Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study — 0.03; -0.01 Log10(percentage of T cells) — p=0.63
Phase 2 N=3 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants